LD-2 disclosure · 2nd Quarter - Report
TEVA PHARMACEUTICALS USA, INC.
Client
- Name
- TEVA PHARMACEUTICALS USA, INC.
- Description
- Pharmaceutical manufacturer
- Location
- New Jersey · United States of America
Registrant
- Description
- Law firm
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
2 issuesHealth Issues
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.
LobbyistsMEGAN SUSSMAN HERBER · mr ELLIOT VICE
Covered position (MEGAN SUSSMAN HERBER): Legislative Director/Senior Legislative Assistant/Legislative Assistant, Rep. Doris Matsui (D-CA) 2014-2018
Covered position (mr ELLIOT VICE): Staff Assistant, Legislative Correspondent & Scheduler, Sen. Evan Bayh (D-IN) 2009-2010
TargetedSENATE · HOUSE OF REPRESENTATIVES · Health & Human Services, Dept of (HHS)
Copyright/Patent/Trademark
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.
LobbyistsMEGAN SUSSMAN HERBER · mr ELLIOT VICE